This is a new cephalosporin (fifth generation). What's unique about it among cephalosporins is activity against MRSA. Like other new antibiotics these days, the FDA approval is limited to a couple of indications. In this case, CAP and skin and skin structure infections. The MRSA approval is for the skin infections only, not for pneumonia. (OK against MSSA in pneumonia, but not MRSA. Not sure why that is, whether it's a penetration issue or just not enough clinical data).
Here's a summary along with prescribing info.